PROPOSED REGULATION TEXT

Title 17. California Code of Regulations

Division 1, Chapter 4, Subchapter 1, Article 1

Amend Section 2505 to read as follows:

§ 2505. Notification by Laboratories.

(a) Through (e)(1) no change to text.

(2) The diseases or agents specified, with the exception of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), shall be reported within one working day after the health care provider or other person authorized to receive the report has been notified. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) shall be reported within eight hours after the health care provider or other person authorized to receive the report has been notified. Laboratories shall transmit these reports to the state electronic reporting system or local electronic reporting system that is linked to the state electronic reporting system, except for acute HIV infection reporting which shall be reported by telephone (see (j) for specific acute HIV infection reporting requirements). Acute HIV infection shall be reported both by telephone and to the state electronic reporting system within one working day of identification. If reporting to the state or local electronic reporting system is not possible, reporting by electronic facsimile transmission or electronic mail may temporarily substitute for reporting to the state or local electronic reporting system. Laboratories shall also report by other means (e.g., electronic facsimile) if requested by a health officer or the Department. Laboratory findings for these diseases are those that satisfy the most recent communicable disease
surveillance case definitions established by the CDC (unless otherwise specified in this Section). The diseases or agents reported pursuant to this requirement are:

- Acid fast bacillus (AFB) (see (g) for additional reporting requirements)
- Anaplasmosis
- Babesiosis

*Bordetella pertussis* acute infection, by culture or molecular identification

- Borrelia burgdorferi infection

- Brucellosis, animal (*Brucella* spp. except *Brucella canis*)

- Campylobacteriosis (*Campylobacter* spp.) (detection or isolation a clinical specimen)

- Carbapenem-resistant Enterobacteriaceae (Carbapenemase-producing)

- Chancroid (*Haemophilus ducreyi*)

- Chikungunya virus infection

*Chlamydia trachomatis* infections, including lymphogranuloma venereum (LGV)

- Coccidioidomycosis

- Cryptosporidiosis

- Cyclosporiasis (*Cyclospora cayetanensis*)

- Dengue virus infection
Diphtheria

Ehrlichiosis

Encephalitis, arboviral

*Escherichia coli* shiga toxin producing (STEC) including *E. coli* O157 (see (m) for additional reporting requirements)

Flavivirus infection of undetermined species

Giardiasis (*Giardia lamblia, intestinalis, or duodenalis*)

Gonorrhea

*Haemophilus influenzae*, all types (detection of or isolation from a sterile site in a person less than 5 years of age)

Hantavirus Infections

Hepatitis A, acute infection

Hepatitis B, acute or chronic infection (specify gender)

Hepatitis C, acute or chronic infection

Hepatitis D (Delta), acute or chronic infection

Hepatitis E, acute infection (detection of hepatitis E virus RNA from a clinical specimen or positive serology)

Human Immunodeficiency Virus (HIV), acute infection (see (j) for additional reporting requirements)
Influenza

Legionellosis (*Legionella spp.*) (antigen or culture)

Leprosy (Hansen Disease) *Mycobacterium leprae*

Leptospirosis *Leptospira spp.*

Listeriosis *Listeria* (see (m) for additional reporting requirements)

Malaria (see (h) for additional reporting requirements)

Measles (Rubeola), acute infection

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Mumps (mumps virus), acute infection

*Neisseria meningitidis* (sterile site isolate or eye specimen) (see (m) for additional reporting requirements)

Poliovirus

Psittacosis Chlamydia psittaci)

Q Fever (*Coxiella burnetii*)

Rabies, animal or human

Relapsing Fever (*Borrelia spp.*) (identification of *Borrelia* spp. spirochetes on peripheral blood smear)

*Rickettsia*, any species, acute infection (detection from a clinical specimen or positive serology)
Rocky Mountain Spotted Fever (*Rickettsia rickettsii*)

Rubella, acute infection

Salmonellosis *Salmonella* spp.) (see Section 2612 (a) for additional reporting requirements)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (see (p) and (q) for additional reporting requirements)

Shiga toxin (detected in feces) (see (m) for additional reporting requirements)

Shigellosis (*Shigella* spp.) (see (m) for additional reporting requirements)

Syphilis

Trichinosis (*Trichinella*)

Tuberculosis, including *Mycobacterium tuberculosis* complex (see (f) for additional reporting requirements)

Latent Tuberculosis Infection identified by a positive laboratory test (see (o) for additional reporting requirements)

Tularemia, animal (*F. tularensis*)

Typhoid

*Vibrio* species infections

West Nile virus infection
Yellow Fever (yellow fever virus)

Yersiniosis (Yersinia spp., non-pestis) (isolation from a clinical specimen)

Zika virus infection (see (m) for additional reporting requirements)

(f) Through (p) no change to text

(q) A laboratory that performs genetic sequencing of SARS-CoV-2 shall submit sequence data to the Department in an electronic format specified by the Department. In addition, a laboratory that identifies a SARS-CoV-2 strain designated as a variant of public health importance by the Department shall transmit the report in a format specified by the Department to the state electronic reporting system or local electronic reporting system that is linked to the state electronic reporting system. The sequence data submission and the strain report shall include the information identified in subsection (c), and the federal Clinical Laboratory Improvement Amendments certificate number if applicable.

Note: Authority cited: Sections 100275, 120125, 120130, 120140, 125095, 131050, 131051, 131052, 131080 and 131200, Health and Safety Code. Reference: Sections 100180, 120125, 120130, 120140, 120175, 120575, 121365, 125100 and 131080, Health and Safety Code; Sections 1209, 1246.5 and 1288, Business and Professions Code; Cal. Const., art. 1, Section 1; and Section 1040, Evidence Code.